Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and chief executive Daniel O’Day. He dubbed lenacapavir – the company’s twice-a ...

Human immunodeficiency virus type 1 (HIV-1) targets important cells of our immune system, making infected individuals more ...

Local AIDS experts are at odds with the United Nations Programme on HIV/AIDS (UNAIDS) over its claims that AIDS could be ...

International recognition for Mainz-based research on altermagnetism, a new concept in physics.

Lenacapavir has been the subject of several studies that highlight its potential as a long-acting treatment for HIV-1. In a phase 3 trial, lenacapavir demonstrated significant antiviral activity ...

It’s all the more tragic because HIV drugs can keep people from catching the virus, and prevent those living with the virus from passing it on. If everyone who needed these drugs could access them, ...

So far, the FDA has approved the drug only for people who already have HIV that’s resistant to other treatments. But its ...

Researchers at the Max Planck Institute of Biophysics and Heidelberg University have observed largely intact HIV-1 capsids as ...

Lenacapavir has the potential to transform HIV care and prevention, but only if access is broadened, according to Jose Abrigo ...

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...

2024 — Recent results from a recent clinical trial indicate that a twice-yearly injection of Lenacapavir offers an overall 96% reduced risk of acquiring ... HIV Latency Reversing Properties in ...